SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-24-014382
Filing Date
2024-05-02
Accepted
2024-05-02 16:18:28
Documents
16
Period of Report
2024-05-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20240430_8k.htm   iXBRL 8-K 25390
2 EXHIBIT 99.1 ex_665434.htm EX-99.1 147321
7 logo.jpg GRAPHIC 3258
  Complete submission text file 0001437749-24-014382.txt   326953

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20240502.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20240502_def.xml EX-101.DEF 11806
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20240502_lab.xml EX-101.LAB 15857
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20240502_pre.xml EX-101.PRE 12021
19 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20240430_8k_htm.xml XML 2944
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 24908578
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)